Cyrille Hulin

18PUBLICATIONS
69CO-AUTHORS
Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Medical infection agents (incl. prions)Medical mycologyGene and molecular therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

|Jun 01, 2026
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.

|Feb 25, 2026
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).

Alexis Talbot, Bernard Delcour, Laurent Gillot

|Oct 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Philippe Moreau, Cyrille Hulin, Alexis Talbot

|Mar 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020.

Laure Vincent, Olivier Decaux, Aurore Perrot

|Feb 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.

Thierry Facon, Philippe Moreau, Katja Weisel

Pageof 3

Frequent Collaborators

12 joint publications

Philippe Moreau

9 joint publications

Aurore Perrot

8 joint publications

Xavier Leleu

7 joint publications

Cyrille Touzeau